Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of ...
Initial data from Ascendis Pharma's Phase 1/2 IL-Believe Trial show 29% (4/14) anti-tumor responses in heavily pre-treated platinum-resistant ovarian cancer patients treated with TransCon IL-2 β/γ plus chemotherapy, with the combination generally well-tolerated.
Reference News
29% of heavily pre-treated platinum-resistant ovarian cancer patients showed anti-tumor responses with TransCon IL-2 β/γ plus chemotherapy, with generally well-tolerated side effects.
Ascendis Pharma's Phase 1/2 IL-Believe Trial showed 29% (4/14) efficacy-evaluable platinum-resistant ovarian cancer (PROC) patients responded to TransCon IL-2 β/γ plus chemotherapy, suggesting clinical activity in heavily pre-treated patients. The treatment was generally well-tolerated, with most adverse events being grade 1 or 2. Results will be presented at ESMO 2024 in Barcelona.
Initial data from Ascendis Pharma's Phase 1/2 IL-Believe Trial show 29% (4/14) anti-tumor responses in heavily pre-treated platinum-resistant ovarian cancer patients treated with TransCon IL-2 β/γ plus chemotherapy, with the combination generally well-tolerated.